NBRP’s mRNA facility accelerates progress in mRNA-related clinical trials

2023-12-31 / GlobalBio & Investment

Thetherapeuticuseof #mRNA hasfueledgreathopetofightabroadrangeofincurablediseases.NotjustagainstCOVID-19butalso craftingpersonalizedcancervaccines!ExcitingnewsawaitsaswehopeforNBRP’smRNAfaciliti...

GBIHighlights HealthcareExpo

Strategies for Medtech Startups to succeed in the US market

2023-12-31 / GlobalBio & Investment

Strategiesfor #medtech #startups tosucceedintheUSmarket?Utilizelocalnetworksandaccessregionalmedicaldata.ExplorefurtherinsightsinGlobalbio'srecapofthe2023MedtechStarthubeventat Healthcare+ExpoTaiw...

GBIHighlights

DAY 2 Reports of BIO Asia-Taiwan 2024

2024-07-25 / GlobalBio & Investment

TheseconddayofBIOAsia–Taiwan2024hasbeenanotherbrilliantdayfullofideas,insightsandinteractionswithprofessionalexperts!Forallourreaders,weareexcitedtoreleaseourlatestreportsofSession4toSession8,wh...

GBIHighlights

Sunny Pharmtech Inc.’s CPA-I successfully dispatched its inaugural shipment on 30th November

2023-12-31 / GlobalBio & Investment

SunnyPharmtechInc.祥翊製藥股份有限公司’sgenericdruginjectable,Cyclophosphamide(CPA-I),successfullydispatcheditsinauguralshipmenton30thNovember,targetinga$100millionmarket.ThisFDA-approvedCPA-I,grantedinla...

GBIHighlights

Meet 'Stress EEG Assessment System' by HippoScreen Neurotech Corp

2023-12-31 / GlobalBio & Investment

Meet'StressEEGAssessmentSystem'by HippoScreenNeurotechCorp. AnAI-poweredsoftwareasmedicaldevice(#SaMD)tomeasurebrainwavestress,andthefirsteverTFDA-certifiedSaMDforaidingthediagnosisofdepressio...

GBIHighlights

BioPreventiveMedicine’s DNlite-IVD103 has approved by SFDA

2023-12-31 / GlobalBio & Investment

“Anounceofpreventionisworthapoundofcure”.Let’sgivearoundofapplauseto #BioPreventiveMedicine’sDNlite-IVD103!Thisstate-of-the-arttestiscapableofpredicting #kidney functiondecline...

子宮頸癌 ADC

輝瑞晚期子宮頸ADC藥Tivdak 獲FDA完全批准

2024-05-02 / 記者彭梓涵

4月29日，輝瑞(Pfizer)宣布，其收購抗體藥物複合體(ADC)開發商Seagen而獲得的ADC藥Tivdak(tisotumabvedotin-tftv)，在治療經化療而復發、晚期轉移性子宮頸癌，取得美國食品藥物管理局(FDA)的完全批准。Tivdak先前已獲得FDA加速批准，此次的批准則是基於一項開放標籤、對照、多中心、隨機的三期試驗，共招募502名復發或轉移性的子宮頸癌患者，這些患者曾接...

GBI Highlights

AdvMeds now serves 12 countries with 3 million+ users worldwide!

2023-12-31 / GlobalBio & Investment

Breakingtheboundaries!AdvMeds,ahealthcareinformationsystemcompanyfromTaiwan,nowserves12countrieswith3million+usersworldwide!DuringCOVID-19,AdvMedsstoodoutbyprovidingdigitalhealthcaresolutionsandpartne...

神經疾病罕見疾病卓飛症候群癲癇阿茲海默症帕金森氏症多發性硬化症狼瘡

Lundbeck砸26億美元收購Longboard、獲癲癇臨床三期新藥

2024-10-15 / 記者吳培安

美國時間14日，丹麥藥廠Lundbeck宣布斥資26億美元現金，收購專長神經學及罕見疾病開發的美國藥廠LongboardPharmaceuticals，進而獲得Longboard旗下的潛力候選新藥bexicaserin，該藥以發育及癲癇性腦病變(developmentalandepilepticencephalopathies,DEE)之癲癇為目標適應症，正在進行卓飛症候群(Dravetsyndr...

GBIHighlights

DAY 1 Reports of BIO Asia-Taiwan 2024

2024-07-24 / GlobalBio & Investment

ThefirstdayofBIOAsia–Taiwan2024hascametotheend.Thanksforallparticipantstojointhiswonderfuleventdespitetheweather.Forallourreaders,weareexcitedtoofferourlatestreportsoftheopeningandthethreeplenar...

GBIHighlights

Leadgene Biomedical, Inc. has partnered with BICO Group's CYTENA and CYTENA BPS

2024-03-31 / GlobalBio & Investment

#CellCollaborationLeadgeneBiomedical,Inc.haspartneredwithBICOGroup'sCYTENAandCYTENABPS(CYTENABioprocessSolutions)tocreateacompetitiveCellLineDevelopment(CLD)platform.Thiscollaborationaimstoenhance...

GBIHighlights

Dr. Aaron Sato visited Taiwan to give a lecture on AI-assisted antibody discovery

2024-04-30 / GlobalBio & Investment

#DrugdiscoveryDr.AaronSato,theChiefScientistOfficerofTwistBioscience,recentlyvisitedTaiwantogivealectureonDNAvariantlibrariesandAI-assistedantibodydiscovery.TheseminarwasheldattheNationalBiotechnology...